Last edition
News about "siRNA Therapy for Rare Cardiomyopathy"
Bayer Partners with Souffle Therapeutics to Develop Heart-Targeted siRNA Therapy
Bayer and Soufflé Therapeutics, a biotechnology company focused on developing cell-selective genetic medicines, have entered into a strategic collaboration and global licensing agreement to advance a heart-targeted small interfering RNA (siRNA) therapy for a rare form of dilated cardiomyopathy.
SiRNA Therapy For Rare Cardiomyopathy | 09/01/2026 | By Darshana | 188
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members